Cargando…

Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas

BACKGROUND: There is a paucity of studies reporting long-term survival outcomes for HPV/p16 positive oropharyngeal squamous cell carcinoma (OPSCC). This study aims to compare long-term outcomes of advanced stage p16 positive and negative OPSCCs, treated by surgical and non-surgical modalities. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Jessica M., Holmes, Emma M., O’Connell, Daniel A., Harris, Jeffrey, Seikaly, Hadi, Biron, Vincent L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258135/
https://www.ncbi.nlm.nih.gov/pubmed/30267774
http://dx.doi.org/10.1016/j.pvr.2018.09.002
_version_ 1783374447683567616
author Clark, Jessica M.
Holmes, Emma M.
O’Connell, Daniel A.
Harris, Jeffrey
Seikaly, Hadi
Biron, Vincent L.
author_facet Clark, Jessica M.
Holmes, Emma M.
O’Connell, Daniel A.
Harris, Jeffrey
Seikaly, Hadi
Biron, Vincent L.
author_sort Clark, Jessica M.
collection PubMed
description BACKGROUND: There is a paucity of studies reporting long-term survival outcomes for HPV/p16 positive oropharyngeal squamous cell carcinoma (OPSCC). This study aims to compare long-term outcomes of advanced stage p16 positive and negative OPSCCs, treated by surgical and non-surgical modalities. METHODS: OPSCC patients from 1998 to 2012 were identified through a prospectively collected cancer registry. P16 immunohistochemistry was used as a surrogate marker for HPV-OPSCC. Overall survival (OS) and aspiration free survival (AFS) comparisons were made between patients treated with chemoradiation (CRT) versus primary surgery and radiation/chemoradiation (S+RT/CRT) at 5, 10 and 15 years post-treatment. RESULTS: A total of 319 patients were included. P16 positive patients and non-smokers had significantly higher long-term (5, 10 and 15-year) OS. Smokers and p16 negative patients treated with S+RT/CRT had improved long-term OS compared to patients who received CRT. Smokers and p16 negative patients had lower long-term AFS. Multivariate analysis showed improved OS was associated with p16 positivity (HR 0.42, 0.28–0.61) and surgery (HR 0.47, 0.32–0.69), whereas lower OS was associated with ECOG ≥ 2 (HR 2.46, 1.61–3.77), smoking (HR 2.37, 1.41–3.99) and higher stage (HR 1.68, 1.05–2.68). CONCLUSIONS: In smokers and p16-negative OPSCC patients, primary surgery may be associated with improved long-term survival and dysphagia-related outcomes.
format Online
Article
Text
id pubmed-6258135
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62581352018-12-03 Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas Clark, Jessica M. Holmes, Emma M. O’Connell, Daniel A. Harris, Jeffrey Seikaly, Hadi Biron, Vincent L. Papillomavirus Res Article BACKGROUND: There is a paucity of studies reporting long-term survival outcomes for HPV/p16 positive oropharyngeal squamous cell carcinoma (OPSCC). This study aims to compare long-term outcomes of advanced stage p16 positive and negative OPSCCs, treated by surgical and non-surgical modalities. METHODS: OPSCC patients from 1998 to 2012 were identified through a prospectively collected cancer registry. P16 immunohistochemistry was used as a surrogate marker for HPV-OPSCC. Overall survival (OS) and aspiration free survival (AFS) comparisons were made between patients treated with chemoradiation (CRT) versus primary surgery and radiation/chemoradiation (S+RT/CRT) at 5, 10 and 15 years post-treatment. RESULTS: A total of 319 patients were included. P16 positive patients and non-smokers had significantly higher long-term (5, 10 and 15-year) OS. Smokers and p16 negative patients treated with S+RT/CRT had improved long-term OS compared to patients who received CRT. Smokers and p16 negative patients had lower long-term AFS. Multivariate analysis showed improved OS was associated with p16 positivity (HR 0.42, 0.28–0.61) and surgery (HR 0.47, 0.32–0.69), whereas lower OS was associated with ECOG ≥ 2 (HR 2.46, 1.61–3.77), smoking (HR 2.37, 1.41–3.99) and higher stage (HR 1.68, 1.05–2.68). CONCLUSIONS: In smokers and p16-negative OPSCC patients, primary surgery may be associated with improved long-term survival and dysphagia-related outcomes. Elsevier 2018-09-26 /pmc/articles/PMC6258135/ /pubmed/30267774 http://dx.doi.org/10.1016/j.pvr.2018.09.002 Text en © 2018 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Clark, Jessica M.
Holmes, Emma M.
O’Connell, Daniel A.
Harris, Jeffrey
Seikaly, Hadi
Biron, Vincent L.
Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
title Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
title_full Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
title_fullStr Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
title_full_unstemmed Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
title_short Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
title_sort long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258135/
https://www.ncbi.nlm.nih.gov/pubmed/30267774
http://dx.doi.org/10.1016/j.pvr.2018.09.002
work_keys_str_mv AT clarkjessicam longtermsurvivalandswallowingoutcomesinadvancedstageoropharyngealsquamouscellcarcinomas
AT holmesemmam longtermsurvivalandswallowingoutcomesinadvancedstageoropharyngealsquamouscellcarcinomas
AT oconnelldaniela longtermsurvivalandswallowingoutcomesinadvancedstageoropharyngealsquamouscellcarcinomas
AT harrisjeffrey longtermsurvivalandswallowingoutcomesinadvancedstageoropharyngealsquamouscellcarcinomas
AT seikalyhadi longtermsurvivalandswallowingoutcomesinadvancedstageoropharyngealsquamouscellcarcinomas
AT bironvincentl longtermsurvivalandswallowingoutcomesinadvancedstageoropharyngealsquamouscellcarcinomas